ARTICLE | Clinical News
Pfizer discontinues Sutent study
July 1, 2009 1:33 AM UTC
Pfizer Inc. (NYSE:PFE) said it discontinued the Phase III SUN 1122 trial to treat metastatic colorectal cancer after an IDMC concluded that Sutent sunitinib plus irinotecan, 5-fluorouracil and leucovo...